Heparin and low-molecular-weight heparin

Thrombosis and Haemostasis

Volumn 99, Issue 5, 2008, Pages 807-818

  Gray, Elaine ^a   Mulloy, Barbara ^a   Barrowcliffe, Trevor W ^a,b  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Heparin; Low molecular weight heparin

Indexed keywords

BEMIPARIN; DALTEPARIN; DEXTRAN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; REVIPARIN; THROMBIN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; CARBON NUCLEAR MAGNETIC RESONANCE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEPOLYMERIZATION; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; HEART INFARCTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG EMBOLISM; MOLECULAR WEIGHT; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RISK REDUCTION; SKIN NECROSIS; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CORONARY ARTERY DISEASE; DRUG MONITORING; FACTOR XA; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; NEOPLASMS; PATIENT SELECTION; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 43949084693     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-01-0032     Document Type: Review

References (133)

1. Mulloy B, Gray E, Barrowcliffe TW. Characterisation of unfractionated heparin samples: Comparison of samples from the last 50 years". Thromb Haemost 2000; 84: 1052-1056.
2. Al Dieri R, Wagenvoord R, van Dedem GW, et al. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif - the C-domain. J Thromb Haemost 2003; 1: 907-914.
3. Sasisekharan R, Raman R, Prabhakar V. Glycomics approach to structure-function relationships of glycosaminoglycans. Annu Rev Biomed Eng 2006; 8: 181-231.
4. Guerrini M, Bisio A, Torri G. Combined quantitative (1)H and (13)C nuclear magnetic resonance spectroscopy for characterization of heparin preparations. Semin Thromb Hemost 2001; 27: 473-482.
5. Lin P-H, Sinha U, Betz A. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa. Biochim Biophys Acta 2001; 1526: 105-113.
6. Monograph 01/2008:0828 Heparins, Low-Molecular_ mass, European Pharmacopoeia 2008; Edition 6.0: 2041-2042.
7. Mulloy B, Gee C, Wheeler S, et al. Molecular weight measurements of low molecular weight heparins by gel permeation chromatography. Thromb Haemost 1997; 77: 668-674.
8. Johnson EA, Kirkwood TB, Stirling Y, et al. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 1976; 35: 586-591.
9. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Haemost 1999; 25 (Suppl 3): 5-16.
10. Rosenberg RD. Actions and interactions of antithrombin and heparin. New Engl J Med 1975; 292: 146-151.
11. Hook M, Bjork I, Hopwood J, et al. Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett. 1976; 66: 90-93.
12. Choay J, Petitou M, Lormeau JC, et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-499.
13. Andersson LO, Barrowcliffe TW, Holmer E, et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583.
14. Lane DA, Macgregor IR, Michalski R, et al. Anticoagulant activities of four unfractionated and fractionated heparins. Thromb Res 1978; 12: 257-271.
15. Barrowcliffe TW, Johnson EA, Eggleton CA, et al. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 1979; 41: 573-583.
16. Holmer E, Lindahl U, Backstrom G, et al. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 1980; 18: 861-869.
17. Thomas DP, Merton RE, Barrowcliffe TW, et al. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemost 1982; 47: 244-248.
18. Barrowcliffe TW, Merton RE, Havercroft SJ, et al. Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides. Thromb Res 1984; 34: 125-133.
19. Lane DA, Denton J, Flynn AM, et al. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732.
20. Pomerantz MW, Owen WG. A catalytic role for heparin. Evidence for a ternary complex of heparin cofactor thrombin and heparin. Biochim Biophys Acta 1978; 535: 66-77.
21. Hoylaerts M, Owen WG, Collen D. Involvement of heparin chain length in the heparin-catalyzed inhibition of thrombin by antithrombin III. J Biol Chem 1984; 259: 5670-5677.
22. Ellis V, Scully MF, Kakkar VV. The relative molecular mass dependence of the anti-factor Xa properties of heparin. Biochem J 1986; 238: 329-333.
23. Barrowcliffe TW, Le Shirley Y. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions. Thromb Haemost 1989; 62: 950-954.
24. Wagenvoord R, Al Dieri R, van Dedem G, et al. Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths. Thromb Res 2008; in press.
25. Barrowcliffe TW, Havercroft SJ, Kemball-Cook G, et al. The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides. Biochem J 1987; 243: 31-37.
26. Ellis V, Scully MF, Kakkar VV. The acceleration of the inhibition of platelet prothrombinase complex by heparin. Biochem J 1986; 233: 161-165.
27. Ofosu FA, Lormeau JC, Craven S, et al. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma. Thromb Haemost 1994; 72: 862-828.
28. Holmer E, Kurachi K, Söderström G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J 1981; 193: 395-400.
29. Colman RW, Scott CF, Pixley RA, et al. Effect of heparin on the inhibition of the contact system enzymes. Ann NY Acad Sci 1989; 556: 95-103.
30. Ofosu FA, Blajchman MA, Modi GJ, et al. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. Br J Haematol 1985; 60: 695-704.
31. Ofosu FA, Hirsh J, Esmon CT, et al. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J 1989; 257: 143-150.
32. Ofosu FA, Barrowcliffe TW. Mechanisms of action of low molecular weight heparins and heparinoids. Baillieres Clin Haematol 1990; 3: 505-529.
33. Barrowcliffe TW, Thomas DP. Anticoagulant activities of heparin and fragments. Ann NY Acad Sci 1989; 556: 132-145.
34. Thomas DP, Merton RE, Gray E, et al. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model. Thromb Haemost 1989; 61: 204-207.
35. Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-462.
36. Béguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989; 61: 397-401.
37. Hemker HC, Wielders S, Kessels H, et al. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-624.
38. Béguin S, Mardiguian J, Lindhout T, et al. The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma. Thromb Haemost 1989; 61: 30-34.
39. Hemker HC. Is anti-factor Xa activity important? J Lab Clin Med 1990; 116: 268.
40. Hemker HC, Béguin S. The activity of heparin in the presence and absence of Ca2+ ions; why the anti-Xa activity of LMWHs is about two times overestimated. Thromb Haemost 1993; 70: 717-718.
41. Barrowcliffe TW, Johnson EA, Thomas DP. Low molecular weight heparin. John Wiley, Chichester 1992.
42. Thomas DP, Merton RE, Barrowcliffe TW, et al. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemost 1982; 47: 244-248.
43. Bauer KA. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis. Am J Orthop 2002; 31 (11 Suppl): 4-10.
44. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003; 109: 1-11.
45. Gray E, Walker AD, Mulloy B, et al. A collaborative study to establish the 5th International Standard for Unfractionated Heparin. Thromb Haemost 2000; 84: 1017-1022.
46. Thomas DP, Curtis AD, Barrowcliffe TW. A collaborative study designed to establish the 4th International Standard for Heparin. Thromb Haemost 1984; 52: 148-153.
47. Barrowcliffe TW, Curtis AD, Tomlinson TP, et al. Standardization of low molecular weight heparins: a collaborative study. Thromb Haemost 1985; 54: 675-679.
48. Barrowcliffe TW, Curtis AD, Johnson EA, et al. An international standard for low molecular weight heparin. Thromb Haemost 1988; 60: 1-7.
49. Crafoord C. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis. Acta Chir Scand Suppl 1936; 79: 407-413.
50. Crafoord C, Jorpes J. Heparin as a prophylaxis against thrombosis. J Am Med Assoc 1941; 111: 2831-2840.
51. Barritt D, Jordan S. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; 1: 1309-1312.
52. Kakkar VV, Corrigan T, Spindler J, et al. Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery. A double-blind, randomised trial. . Lancet 1972; 2: 101-106.
53. Collins R, Scrimgeour A, Yusef S, et al. Reductions in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic and urological surgery. N Engl J Med 1988; 318: 1162-1173.
54. Kakkar VV, Djazaeri B, Fok J, et al. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. Brit Med J 1982; 284: 375-379.
55. Kakkar VV, Murray WJG. Efficacy and safety of low-molecular-weight- heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Brit J Surg 1985; 72: 786-791.
56. Schmitz-Huebner U, Bunte H, Freise G, et al. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Woch 1984; 62: 349-353.
57. Koller M Schoch U, Buchmann P, et al. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized double-blind study versus unfractionated heparin. Thromb Haemost 1986; 56: 243-246.
58. Bergvist D, Burmark US, Frisell J, et al. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Brit J Surg 1986; 73: 2004-208.
59. Bergvist D Mätzsch T, Burmark US, et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Brit J Surg 1988; 75: 888-891.
60. Caen JP (A French Multicenter Trial). A randomized double blind study between low molecular weight heparin (Kabi 2165) and standard heparin in the prevention of deep vein thrombosis in general surgery. Thomb Haemost 1988; 59: 216-220.
61. Samama M, Bernard P, Bonnardot JP, et al.; GENOX multicentric trial. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Brit J Surg 1988; 75: 128-131.
62. Breddin HK. Prophylaxis and treatment of deep-vein thrombosis. Sem thromb Haemost 2000; 26 (Suppl 1): 47-52.
63. Turpie AGG, Levine MN, Hirsh J, et al. A randomized controlled trials of a lo-molecular-weight heparin (Enoxparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929.
64. Eriksson BI, Zachrisson BE, Teger-Nilsson AC, et al. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Brit J Surg 1988; 75: 1053-1057.
65. Mätzsch T, Bergqvist D, Fredin H, et al. Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir Scand Suppl 1988; 543: 80-84.
66. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost. 1988; 60: 407-410.
67. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114: 545-551.
68. Levine MN, Hirsh J. Clinical potential of low molecular weight heparins. In: Bailliere's Clinical Haematology - Antihrombotic Therapy. Ed J Hirsh. Bailliere Tindall 1990; 3: 545-554.
69. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximalvein thrombosis. N Engl J Med 1992; 326: 975-982.
70. Lindmarker P, Holmström M, Granqvist S, et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-190.
71. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681.
72. Hull RD, Pineo GF. Low-molecular-weight heparins in the treatment of venous thromboembolism. Sem Thromb Haemost 2000; 26 (Suppl 1): 61-67.
73. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-920.
74. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-156.
75. Leizorovicz A, Simonneau G, Decousus H, et al. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. Br Med J 1994; 309: 299-304.
76. Hirsh J, Siragusa S, Cosmi B, et al. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995; 74: 360-363.
77. Kakkar VV, Boeckl O, Boneu B, et al. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg 1997; 21: 2-8.
78. Hartl P, Brücke P, Dienstl E, et al. Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res 1990; 57: 577-584.
79. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-662.
80. Hull RD. Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings. Thromb Haemost 2008; 99: 502-510.
81. Théroux P, Waters D, Qiu S, et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88: 2045-2048.
82. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994; 89: 81-88.
83. Gurfinkel EP, Manos EJ, Mejaíl RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26: 313-318.
84. The FRAX.I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999; 20: 1553-1562.
85. Cohen M. The role of low-molecular-weight heparin in arterial diseases: optimizing antithrombotic therapy. Thromb Res 2000; 100: 131-139.
86. Cohen M, Demers C, Gurfinkel EP, et al., for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-452.
87. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-1601.
88. Zeymer U, Gitt A, Jünger C, et al. Efficacy and safety of enoxaparin in unselected patients with STsegment elevation myocardial infarction. Thromb Haemost 2008; 99: 150-154.
89. Turpie AGG. Antithrombotics and anticoagulants in coronary syndromes. Sem Thromb Haemost 2000; 26 (Suppl 1): 79-83.
90. Zacharski LR, Ornstein, DL. Heparin and cancer. Thromb Haemost 1998; 80: 10-23.
91. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269-277.
92. Lensing AW, Prins MH, Davidson BL, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995; 155: 601-607.
93. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-1735.
94. Lee AY, Levine MN, Baker RI, et al.; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
95. Monreal M, Zacharski L, Jiménez JA, et al. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2004; 2: 1311-1315.
96. Kuderer NM, Khorana AA, Lyman H, et al. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complication. Cancer 2007; 110: 1149-1161.
97. Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 2007; 18: CD006652.
98. Tagalakis V, Blostein M, Robinson-Cohen C, et al. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat Rev 2007; 33: 358-368.
99. Einstein MH, Fritts EA, Hartenbach EM. Venous thromboembolism prevention in gynaecologic cancer surgery: a systematic review. Gynecol Oncol 2007; 105: 813-819.
100. Nishioka J, Goodin S. Low molecular weight heparin in cancer associated thrombosis: treatment, secondary prevention, and survival. J Oncol Pharm Pract 2007; 13: 85-97.
101. Lazo-Langner A, Goss GD, Spaans JN, et al. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007; 5: 729-737.
102. Meister B, Kropshofer G, Klein-Franke A, et al. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; Epub ahead of print.
103. Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the efficacy of cis-platinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007; 95: 507-512.
104. Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994; 72: 330-334.
105. Laposata M, Green D, Van Cott ENM, et al. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122: 799-807.
106. Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J Thromb Haemost 2004; 2: 547-550.
107. Bounameaux H, De Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004; 2: 551-554.
108. Hirsh J. Laboratory monitoring of low-molecular-weight heparin therapy. J Thromb Haemost 2004; 2: 1003-1003.
109. Boneu B. Laboratory monitoring of low-molecular-weight heparin therapy - part II. J Thromb Haemost 2005; 3: 573-574.
110. Ostergaard PB, Nilsson B, Bergqvist D, et al. The effect of low molecular weight heparin on experimental thrombosis and haemostasis -the influence of production method. Thromb Res 1987; 45: 739-749.
111. van der Heijden JF, Prins MH, Büller HR. For the initial treatment of venous thromboembolism: are all low-molecular -weight heparin compounds the same? Thromb Res 2000; 100: 121-130.
112. Prandoni P. Low molecular weight heparins: are they interchangeable? Yes. J Thromb Haemost 2003; 1: 10-11.
113. Nenci GG. Low molecular weight heparins: are they interchangeable? No. J Thromb Haemost 2003; 1: 12-13.
114. Cohen M. Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction. Semin Thromb Haemost 1999; 25 (Suppl 3): 111-119.
115. Planès A. An equivalence study of two low-molecular-weight heparins in the prevention and treatment of deep-vein thrombosis after total hip replacement. Semin Thromb Hemost 2000; 26 (Suppl 1): 57-60.
116. Planes A. Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery. Blood Coagul Fibrinolysis 1993; 4 (Suppl 1): S33-35.
117. Planès A, Vochelle N, Fagola M, et al. Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coag Fibrinolysis 1998; 9: 499-505.
118. Navarro-Quilis A, Castellet E, Rocha E, et al.; Bemiparin Study Group in Knee Arthroplasty. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J Thromb Haemost 2003; 1: 425-432.
119. Simonneau G, Laporte S, Mismetti P, et al.; FX140 Study Investigators. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost 2006; 4: 1693-1700.
120. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-1840.
121. Büller HR, Davidson BL, Decousus H, et al.; Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-873.
122. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
123. Papadopoulos S, Flynn JD, Lewis DA. Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Pharmacotherapy 2007; 27: 921-926.
124. Lobo B, Finch C, Howard A, et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99: 208-214.
125. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2655.
126. Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2007; 21: 589-607.
127. Handschin AE, Trentz O, Kock HJ, et al. Low molecular weight heparin-induced skin necrosis-a systematic review. Langenbecks Arch Surg 2005; 390: 249-254.
128. Gaigl Z, Pfeuffer P, Raith P, et al. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br J Haematol 2005; 128: 389-392.
129. O'Meara AC, Demarmels Biasiutti F, Heizmann M. Fondaparinux as an alternative therapy in heparin-induced delayed-type hypersensitivity skin lesions. Thromb Haemost 2007; 98: 1389-1391.
130. Muir JM, Hirsh J, Weitz JI, et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997; 89: 3236-3242.
131. Mätzsch T, Bergqvist D, Hedner U, et al. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost 1990; 63: 505-509.
132. Monreal M, Viñas L, Monreal L, et al. Heparin-related osteoporosis in rats. A comparative study between unfractioned heparin and a low-molecular-weight heparin. Haemostasis 1990; 20: 204-207.
133. Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.